The effect of exercise training on endothelial function in postmenopausal women with breast cancer under aromatase inhibitor therapy.

Mayr, B; Reich, B; Greil, R; Niebauer, J. Cancer Med. 2022 Dec;11(24):4946-4953. doi: 10.1002/cam4.4833. Epub 2022 May 18.

DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.

Starzer, AM; Heller, G; Tomasich, E; Melchardt, T; Feldmann, K; Hatziioan-nou, T; Traint, S; Minichsdorfer, C; Schwarz-Nemec, U; Nackenhorst, M; Mul-lauer, L; Preusser, M; Berghoff, AS; Fuereder, T. J Immunother Cancer. 2022 Mar;10(3):e003420. doi: 10.1136/jitc-2021-003420.

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

Zhou, Q; Gampenrieder, SP; Frantal, S; Rinnerthaler, G; Singer, CF; Egle, D; Pfeiler, G; Bartsch, R; Wette, V; Pichler, A; Petru, E; Dubsky, PC; Bago-Horvath, Z; Fesl, C; Rudas, M; Ståhlberg, A; Graf, R; Weber, S; Dandachi, N; Filipits, M; Gnant, M; Balic, M; Heitzer, E. Clin Cancer Res. 2022 Feb 15;28(4):697-707. doi: 10.1158/1078-0432.CCR-21-3231.

Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.

Rischin, D; Harrington, KJ; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyrri, A; Brana, I; Neupane, P; Bratland, A; Fuereder, T; Hughes, BGM; Me-sia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Hong, RL; Mendoza, RG; Jia, LY; Chirovsky, D; Norquist, J; Jin, F; Burtness, B. Oral Oncol. 2022 May;128:105815. doi: 10.1016/j.oraloncology.2022.105815. Epub 2022 Apr 2.

Polatuzumab bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.

Tam, CS; Brown, JR; Kahl, BS; Ghia, P; Giannopoulos, K; Jurczak, W; Simko-vic, M; Shadman, M; Osterborg, A; Laurenti, L; Walker, P; Opat, S; Chan, HR; Ciepluch, H; Greil, R; Tani, M; Trneny, M; Brander, DM; Flinn, IW; Grosicki, S; Verner, E; Tedeschi, A; Li, JY; Tian, T; Zhou, L; Marimpietri, C; Paik, JC; Co-hen, A; Huang, JN; Robak, T; Hillmen, P. Lancet Oncol. 2022 Aug;23(8):1031-1043. doi: 10.1016/S1470-2045(22)00293-5. Epub 2022 Jul 7.

Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18.

Minichsdorfer, C; Fuereder, T; Leutner, M; Singer, CF; Kacerovsky-Strobl, S; Egle, D; Greil, R; Balic, M; Fitzal, F; Pfeiler, G; Frantal, S; Bartsch, R; Gnant, M. ESMO Open. 2022 Apr;7(2):100426. doi: 10.1016/j.esmoop.2022.100426. Epub 2022 Mar 22.

Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-Group.

Leisch, M; Pfeilstocker, M; Stauder, R; Heibl, S; Sill, H; Girschikofsky, M; Stampfl-Mattersberger, M; Tinchon, C; Hartmann, B; Petzer, A; Schreder, M; Kiesl, D; Vallet, S; Egle, A; Melchardt, T; Piringer, G; Zebisch, A; Machherndl-Spandl, S; Wolf, D; Keil, F; Drost, M; Greil, R; Pleyer, L. Cancers (Basel). 2022 May 17;14(10):2459. doi: 10.3390/cancers14102459.

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advan-ced breast cancer: NeoTRIP Michelangelo randomized study.

Gianni, L; Huang, CS; Egle, D; Bermejo, B; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Bianchini, G; Russo, S; Ciruelos, EM; Greil, R; Semiglazov, V; Colleoni, M; Kelly, C; Mariani, G; Del Mastro, L; Maffeis, I; Valagussa, P; Viale, G. Ann Oncol. 2022 May;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004. E-pub 2022 Feb 17.

Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.

Burtness, B; Rischin, D; Greil, R; Soulieres, D; Tahara, M; de Castro, G; Psyr-ri, A; Brana, I; Baste, N; Neupane, P; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Ge, J; Swaby, RF; Gu-muscu, B; Harrington, K. J Clin Oncol. 2022 Jul 20;40(21):2321-2332. doi: 10.1200/JCO.21.02198. E-pub 2022 Mar 25.

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

Ader, F; Bouscambert-Duchamp, M; Hites, M; Peiffer-Smadja, N; Poissy, J; Belhadi, D; Diallo, A; Lê, MP; Peytavin, G; Staub, T; Greil, R; Guedj, J; Paiva, JA; Costagliola, D; Yazdanpanah, Y; Burdet, C; Mentré, F. Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14.